2024-02-05 05:07:24 ET
Summary
- Prelude Therapeutics is a clinical-stage biopharma developing targeted therapies for different cancers.
- PRLD has three drugs in clinical testing, including a degrader of a protein involved in cell division and a CDK9 inhibitor.
- The company has a strong cash position but may not have enough funding to reach important data readouts, making it a "hold and watch" investment.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Prelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buy